All News Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Delayed Bombay S.E. Other stock markets 01:10:35 29/04/2024 pm IST			5-day change	1st Jan Change
2,396 ^INR	+0.36%		+5.88%	-6.78%

26/04	Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	CI
18/03	Dr Lal Pathlabs Names CEO	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024	26/04	CI
Dr Lal Pathlabs Names CEO	18/03	MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024	17/03	CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer	03/03	CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral	05/02	MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates	02/02	MT
Dr. Lal PathLabs Seeks M&A	01/02	CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024	01/02
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests	01/02	RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24	01/02	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01/02	CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024	25/01	MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002	06/11	MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5%	03/11	MT
Transcript : Dr. Lal PathLabs Limited, H1 2024 Earnings Call, Nov 02, 2023	02/11
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	02/11	CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023	12/23/12	CI
Dr. Lal PathLabs Limited Announces Change in Directorate	20/23/20	CI
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q1; Revenue Meets Estimates	31/23/31	MT
Nomura Downgrades Dr. Lal Pathlabs to Reduce From Neutral, Adjusts Price Target to INR2,002 From INR1,835	31/23/31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

All News

Filters